9 April 2018 - Following assessment of bids in PHARMAC’s 2017/18 annual Invitation to Tender, PHARMAC is proposing to remove the Special Authority and hospital restrictions that currently apply to all strengths of candesartan.

PHARMAC has not yet made a decision on the presentations in the tender, so the brand names, pricing and timing for these changes, if they were to be implemented, is still to be determined. 

PHARMAC is seeking feedback on the proposal to remove the funding restrictions for candesartan.

Read PHARMAC Consultation